Stock Ratings / Health Care / CVRX / financials

NEPH (73) XTNT (69) TELA (36) DRIO (36) ⌘ Pro Terminal →

CVRx Inc. (CVRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is CVRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CVRx Inc. (NASDAQ: CVRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (+1.79% 1D, market cap $38.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CVRX ranks #556 in composite RQD confidence.

Q: How does CVRX compare to NEPH and XTNT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CVRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 85.3%, and ROIC of -35.0%. By comparison, NEPH (Nephros Inc.) holds a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M) and XTNT (Xtant Medical Holdings Inc.) posts a C+ grade (69/100 RQD, P/E N/A, ROIC 12.8%, cap $40.7M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for CVRX?

Per CVRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001235912), CVRx Inc. generated $56.7M in revenue (+10.4% YoY), -$53.3M in net income, and -$40.8M in free cash flow against $104.8M in total assets and $49.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is CVRX trading relative to its 50-day, 200-day, and 52-week technical levels?

CVRX last traded at $1.43 (+1.79% on volume of 257,051 shares), positioning the stock -36.73% below its 50-day simple moving average ($2.26) and -72.92% below its 200-day simple moving average ($5.28). Across its 52-week range of $1.25 to $11.30, CVRX sits at the 1.8% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).

Q: How profitable is CVRx Inc. (CVRX)?

In FY 2025 (10-K), CVRX converted $56.7M of revenue into a 85.3% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.43 +1.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.43

CVRx Inc. (CVRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $38.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.43 (+0.13%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CVRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY CVRX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.9 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.58-17.7% Next Q

Q2 (-2Q)

Grade D$1.30+9.2% Next Q

Q3 (-1Q)

Grade D$1.42+0.7% Next Q

Current

Grade D-$1.43-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CVRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CVRX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.50) forces dealer call-delta covering toward $11.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CVRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CVRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CVRX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $39.3M

FY24

Rev $51.3M

FY25

Rev $56.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$56.7M	85.3%	-80%	-$53.3M	-$40.8M	-45%
FY 2024	$51.3M	83.8%	-80%	-$60.0M	-$40.5M	-45%
FY 2023	$39.3M	85.3%	-80%	-$41.2M	-$39.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CVRX)

✓Walkthrough of CVRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CVRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.96%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.41H $1.46L $1.38C $1.43VOL 272.7K

RES: $4.02SUP: $1.05SMA50: $2.26SMA200: $5.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CVRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CVRX Butterfly Map → + Track CVRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CVRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CVRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CVRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CVRX)

Health Care Rank #556 of 1016 ⚔️ NEPH vs CVRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CVRX vs. NEPH, XTNT, TELA, DRIO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CVRx Inc. (CVRX) ranks #556 by composite RQD confidence (43/100, grade D-) and #782 by equity capitalization ($38.0M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with CVRX at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CVRX ACTIVE CVRx Inc.	D-	43/100	—	85.3%	-35.0%	+1.79%	$38.0M	Benchmark Subject
NEPH Nephros Inc.	B	73/100	29.8x	61.9%	18.9%	+3.16%	$35.5M	/neph-vs-cvrx →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-cvrx →
TELA TELA Bio Inc.	D-	36/100	—	67.7%	-35.0%	-5.74%	$41.5M	/tela-vs-cvrx →
DRIO DarioHealth Corp.	D-	36/100	—	56.6%	-35.0%	-2.93%	$32.4M	/drio-vs-cvrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001235912

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CVRx Inc. (CVRX) reported GAAP revenue of $56.7M (+10.4% vs. FY2024 revenue of $51.3M , and +44.2% cumulative change since FY2023) , GAAP net income of -$53.3M, operating cash flow of -$40.2M, and free cash flow of -$40.8M (-0.6% YoY). On the balance sheet, CVRX closed FY2025 with $104.8M in total assets against $49.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$56.7M	-$53.3M	-$40.2M	-$40.8M	$104.8M	$49.5M
FY2024 (FY)	2024-12-31	$51.3M	-$60.0M	-$39.1M	-$40.5M	$133.4M	$49.3M
FY2023 (FY)	2023-12-31	$39.3M	-$41.2M	-$39.0M	-$39.0M	—	—

3. CVRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CVRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CVRx Inc. (NASDAQ: CVRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (+1.79% 1D, market cap $38.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CVRX ranks #556 in composite RQD confidence.

How does CVRX compare to NEPH and XTNT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CVRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 85.3%, and ROIC of -35.0%. By comparison, NEPH (Nephros Inc.) holds a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M) and XTNT (Xtant Medical Holdings Inc.) posts a C+ grade (69/100 RQD, P/E N/A, ROIC 12.8%, cap $40.7M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CVRX?

Per CVRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001235912), CVRx Inc. generated $56.7M in revenue (+10.4% YoY), -$53.3M in net income, and -$40.8M in free cash flow against $104.8M in total assets and $49.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CVRX trading relative to its 50-day, 200-day, and 52-week technical levels?

CVRX last traded at $1.43 (+1.79% on volume of 257,051 shares), positioning the stock -36.73% below its 50-day simple moving average ($2.26) and -72.92% below its 200-day simple moving average ($5.28). Across its 52-week range of $1.25 to $11.30, CVRX sits at the 1.8% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).